DOCSLIB.ORG

Molecular Changes in Neurons in Multiple Sclerosis: Altered Axonal Expression of Nav1.2 and Nav1.6 Sodium Channels and Na Ca

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Changes in Neurons in Multiple Sclerosis: Altered Axonal Expression of Nav1.2 and Nav1.6 Sodium Channels and Na Ca Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na؉͞Ca2؉ exchanger Matthew J. Craner*†, Jia Newcombe‡, Joel A. Black*†, Caroline Hartle‡, M. Louise Cuzner‡, and Stephen G. Waxman*†§ *Department of Neurology and Paralyzed Veterans of America͞Eastern Paralyzed Veterans Association Neuroscience Research Center, Yale School of Medicine, New Haven, CT 06510; †Rehabilitation Research Center, Veterans Affairs Medical Center, West Haven, CT 06516; and ‡Department of Neuroinflammation, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom Communicated by Dominick P. Purpura, Albert Einstein College of Medicine, Bronx, NY, April 19, 2004 (received for review February 12, 2004) Although voltage-gated sodium channels are known to be de- density of sodium channels in chronically demyelinated axons ployed along experimentally demyelinated axons, the molecular but do not reveal the isoforms of the channels. A 4-fold increase identities of the sodium channels expressed along axons in human in saxitoxin-binding sites in demyelinated white matter from MS demyelinating diseases such as multiple sclerosis (MS) have not patients also suggests the deployment of new Na channels (30) been determined. Here we demonstrate changes in the expression but gives no clues about the channel isoform(s) that are ex- of sodium channels in demyelinated axons in MS, with Nav1.6 pressed. confined to nodes of Ranvier in controls but with diffuse distribu- Recent studies have demonstrated up-regulated expression of tion of Na 1.2 and Na 1.6 along extensive regions of demyelinated v v Nav1.2 and Nav1.6 along extensive regions of demyelinated axons axons within acute MS plaques. Using triple-labeled fluorescent in EAE (4, 31). Nav1.2 channels produce rapidly activating and immunocytochemistry, we also show that Nav1.6, which is known inactivating currents (32–34) and appear to support action- ؉͞ 2؉ to produce a persistent sodium current, and the Na Ca ex- potential conduction, which occurs before myelination (35, 36), changer, which can be driven by persistent sodium current to suggesting that newly produced Nav1.2 channels can support import damaging levels of calcium into axons, are colocalized with conduction in demyelinated axons. Na 1.6 channels, on the other ␤ v -amyloid precursor protein, a marker of axonal injury, in acute MS hand, produce a persistent current in addition to rapidly acti- lesions. Our results demonstrate the molecular identities of the vating and inactivating currents (33, 37, 38), and Nav1.6 is sodium channels expressed along demyelinated and degenerating coexpressed together with the Naϩ͞Ca2ϩ exchanger (NCX) ؉͞ 2؉ axons in MS and suggest that coexpression of Nav1.6 and Na Ca along degenerating axons in EAE (31). exchanger is associated with axonal degeneration in MS. In this study, we present an analysis of Nav1.6 and Nav1.2 sodium channels, and of the NCX, in white matter from the demyelinating diseases ͉ action potential conduction ͉ axonal human CNS, obtained postmortem from patients with secondary degeneration progressive MS, and from control subjects with no neurological disease. We demonstrate that there are changes in the pattern of ine genes encode distinct voltage-gated sodium channels expression of sodium channels along demyelinated CNS axons in N(Nav1.1–Nav1.9) with a common motif but with different MS, with expression of Nav1.6 confined to nodes of Ranvier in amino acid sequences and physiological characteristics (1). control white matter and with diffuse expression of both Nav1.2 Nav1.6 is the major sodium channel, which is clustered at the and Nav1.6 along extensive regions of demyelinated axons in MS. nodes of Ranvier (2), although Nav1.2 is also present at some We also show that Nav1.6 (but not Nav1.2), coexpressed with the nodes (3, 4). However, the identity of sodium-channel isoforms NCX, is associated with axonal injury in MS. that are present along demyelinated axons in disorders such as multiple sclerosis (MS) has not been established. In MS, the loss Materials and Methods of myelin produces failure of axonal action-potential conduction MS Tissue. Postmortem cervical spinal cord and optic nerve that is associated with clinical exacerbations, but axonal con- tissue, acquired by means of a rapid protocol from patients with duction can recover as a result of expression of new sodium disabling secondary progressive MS (n ϭ 7; 46.1 Ϯ 6.5 yr, mean channels along demyelinated axons, providing a substrate for disease duration 14.0 Ϯ 3.7 yr) and from controls (n ϭ 6; 66.4 Ϯ remission of clinical deficits (5). Axonal degeneration also 6.0 yr) with no neurological disease, was obtained from the occurs in MS, contributes to persistent neurological deficits NeuroResource tissue bank (Institute of Neurology, London) (6–9), and may involve persistently activated sodium channels 3 ϩ ϩ (39); 1-cm tissue blocks were placed in OCT mounting medium that drive injurious reverse Na ͞Ca2 exchange (10, 11). Block- (Lamb, London) on cork discs, then gently stirred for9sin ing of sodium channels prevents axonal degeneration within isopentane precooled in liquid nitrogen before storage in air- white matter tracts in a variety of disease models (11–17), tight containers at Ϫ80°C. All tissue analyzed was characterized including a model of MS, experimental autoimmune encepha- ␮ lomyelitis (EAE) (18, 19). by oil red O and hematoxylin staining of 10 m sections taken in triplicate, i.e., immediately before, in the middle, and imme- During the development of myelinated CNS tracts, Nav1.2 channels [which are also present along unmyelinated axons (3, diately after serial sections cut from each tissue block. Acute MS 20, 21)] are initially expressed along premyelinated axons, with lesions with ongoing or recent demyelination were identified on the basis of the presence of substantial numbers (graded as Ն3 a transition to clusters of Nav1.6 at mature nodes of Ranvier (3, 22). In dysmyelinated axons from Shiverer mice, Nav1.2 channels are retained, and Nav1.6 is not expressed (3, 23), and in axons ͞Ϫ Abbreviations: MS, multiple sclerosis; MBP, myelin basic protein; ␤-APP, ␤-amyloid precur- from Plp mice, which myelinate normally and then lose their sor protein; NCX, Naϩ͞Caϩ exchanger; EAE, experimental autoimmune encephalomyelitis. myelin, there is a loss of Nav1.6 clustering and increased expres- §To whom correspondence should be addressed at: Department of Neurology LCI 707, Yale sion of Nav1.2 (24). Electrophysiological (25), cytochemical (26), School of Medicine, 15 York Street, New Haven, CT 06520-8018. E-mail: stephen.waxman and immunocytochemical (27–29) studies using pan-specific @yale.edu. sodium-channel antibodies demonstrate a higher-than-normal © 2004 by The National Academy of Sciences of the USA 8168–8173 ͉ PNAS ͉ May 25, 2004 ͉ vol. 101 ͉ no. 21 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0402765101 Downloaded by guest on October 1, 2021 ona0–5 scale) of oil red O-positive macrophages, containing neutral lipids resulting from myelin breakdown (40). Immunocytochemistry. Tissue sections were processed for immu- nocytochemistry as described (4, 31). Briefly, sections were incubated simultaneously or in combination with anti-myelin basic protein (MBP) mouse IgG (1:4,000; Sternberger Mono- clonals, Lutherville, MD), anti-␤-amyloid precursor protein (␤-APP) mouse IgG (1:100; Chemicon), anti-Caspr mouse IgG [1:500; provided by M. Rasband, University of Connecticut, Farmington (36)] or anti-NCX mouse IgM [NCX1 isoform, shown to be expressed in white matter axons (41)] (1:200; RDI, Flanders, NJ), anti-phosphorylated neurofilament (SMI-31, 1:20,000; Sternberger), anti-nonphosphorylated neurofilament (SMI-32, 1:20,000; Sternberger Monoclonals), and rabbit poly- clonal antibodies to Nav1.6 (residues 1042–1061; 1:100; Alomone, Jerusalem) or Nav1.2 (residues 467–485; 1:100; Alomone). Sections were then washed in PBS, incubated with appropriate secondary antibodies, comprising goat anti-rabbit IgG-Cy3 (1:2,000; Amersham Biosciences), goat anti-mouse IgG-Alexa Fluor 488 (1:1,000; Molecular Probes), goat anti- mouse IgM-Alexa Fluor 488 (1:1,000; Molecular Probes), and goat anti-mouse IgG-Cy5 (1:200, Rockland, Gilbertsville, PA), in blocking solution for 3 h, washed in PBS, and mounted. Biotin- ylated Ricinus communis agglutinin 1 (1:200; Vector Laborato- ries) was used as a microglial͞macrophage marker (42) and reacted with streptavidin-Cy5 (1:350; Amersham Biosciences) for detection. Control experiments, which included the omission of primary or secondary antibodies, showed no staining (data not shown). Tissue Analysis. For analysis of sections, multiple representative images were accrued by confocal microscopy with a Nikon Eclipse E600 microscope. Analysis was confined to images in which axons were sectioned longitudinally as evident from the presence of linear (presumably demyelinated) axonal profiles Fig. 1. Nav1.6 and Nav1.2 sodium channels are expressed along extensive with diffuse sodium-channel immunoreactivity, running for regions of demyelinated axons in MS. Shown are representative images Ͼ20–30 ␮m along the fiber tract within the plane of single demonstrating sections of white matter from spinal cord (A–D) and optic sections. nerve (E and F) immunostained for MBP (green) as a marker of myelination In contrast to control white matter in which there was focal and for sodium channels Nav1.6 (A, C, and E; red) and Nav1.2 (B, D, and F; red). Control spinal cord white matter (A and B) demonstrates robust MBP immu- expression of Nav1.6 and absence of Nav1.2 at nodes of Ranvier nostaining consistent with myelinated axons and does not display axonal (delineated by Caspr immunolabeling), we observed multiple profiles with diffuse (Ͼ10 ␮m) sodium-channel immunostaining. Small foci of ͞ extensive regions of diffuse Nav1.2 and or Nav1.6 sodium- Nav1.6 immunostaining (A; yellow arrows) are present, consistent with the NEUROSCIENCE channel immunoreactivity along demyelinated (demonstrated by focal distribution of Nav1.6 at nodes of Ranvier in control spinal cord white the lack of MBP immunostaining) axons (Figs.
Load more

Recommended publications
  • Center for Peripheral Neuropathy.Pdf
    The Center for Peripheral Neuropathy Department of Neurology The University of Chicago 5841 South Maryland Avenue, MC2030 Chicago, Illinois 60637 Director, Center for Peripheral Neuropathy Brian Popko, Ph.D. Phone: 773.702.4953 Fax: 773.702.5577 Appointments: 773-702-5659 Website: http://PeripheralNeuropathyCenter.uchicago.edu Faculty and Administration Brian Popko, Ph.D. Jack Miller Professor in Neurological Diseases and Associate Chair for Research, Department of Neurology Raymond P. Roos, M.D. Professor, Department of Neurology Betty Soliven, M.D. Associate Professor, Department of Neurology Robert Wollmann, M.D., Ph.D. Professor, Departments of Pathology and Neurology Center for Peripheral Neuropathy The peripheral nervous system transmits vital communications between the brain, spinal cord, and all other parts of the body. The disorder known as peripheral neuropathy interferes with this critical messaging system, resulting in sensory abnormalities that cause pain, numbness, or motor problems that lead to difficulties with movement or muscle control. While certain conditions may contribute to the development of peripheral neuropathy—diabetes, infections, alcoholism, heredity, and exposure to chemicals and certain medications—often a specific cause is unknown. There are so many different types of peripheral neuropathy that, despite its prevalence, relatively little is known about the disease process, prevention, and the most effective treatments. There is an enormous need to learn more about peripheral nerve biology at the basic level
    [Show full text]
  • Axonal Conduction and Injury in Multiple Sclerosis: the Role of Sodium Channels
    REVIEWS Axonal conduction and injury in multiple sclerosis: the role of sodium channels Stephen G. Waxman Abstract | Multiple sclerosis (MS) is the most common cause of neurological disability in young adults. Recent studies have implicated specific sodium channel isoforms as having an important role in several aspects of the pathophysiology of MS, including the restoration of impulse conduction after demyelination, axonal degeneration and the mistuning of Purkinje neurons that leads to cerebellar dysfunction. By manipulating the activity of these channels or their expression, it might be possible to develop new therapeutic approaches that will prevent or limit disability in MS. Nodes of Ranvier Multiple sclerosis (MS) is the most common neurological contribute to axonal degeneration, and the possibility of + Small gaps in the myelin cause of disability in young adults in industrialized societies. a role for a third Na channel isoform in the mistuning of sheath along myelinated fibres. It is usually diagnosed between the ages of 20 and 40, and cerebellar Purkinje neurons, which perturbs the pattern Nodes of Ranvier extend ~1 is called ‘multiple’ sclerosis because most patients have of activity of these cells. μm along the fibre, and are separated by segments of multiple attacks separated both in time and in space, in + myelin that extend for tens or, which different parts of the CNS can be involved (for Na channels and axonal conduction more commonly, hundreds of example, involvement of the optic nerve can cause uni- The disease process in MS attacks myelinated axons, micrometres. lateral visual loss, whereas involvement of spinal sensory denuding them of myelin or causing them to degener- tracts can cause numbness).
    [Show full text]
  • Sodium Channels and Neuroprotection in Multiple Sclerosis—Current Status Stephen G Waxman
    REVIEW www.nature.com/clinicalpractice/neuro Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis—current status Stephen G Waxman SUMMARY INTRODUCTION The past decade has seen increasing interest in Sodium channels can provide a route for a persistent influx of sodium ions the possibility of neuroprotective therapy with into neurons. Over the past decade, it has emerged that sustained sodium sodium channel blockers in multiple sclerosis influx can, in turn, trigger calcium ion influx, which produces axonal injury (MS), as a result of recognition that axon degen- in neuroinflammatory disorders such as multiple sclerosis (MS). The development of sodium channel blockers as potential neuroprotectants eration is a major contributor to disability in in MS has proceeded rapidly, and two clinical trials are currently ongoing. MS, and the demonstration of a critical role The route from the laboratory to the clinic includes some complex turns, for sodium channels in degeneration of CNS however, and a third trial was recently put on hold because of new data axons. This area is one of rapid flux—5 years that suggested that sodium channel blockers might have multiple, complex ago sodium channel blockers had not been actions. This article reviews the development of the concept of sodium studied in animal models of MS, and 2 years channel blockers as neuroprotectants in MS, the path from laboratory to ago clinical studies had not begun to assess the clinic, and the current status of research in this area. protective effects of sodium channel blockers in humans with MS. Now, however, data are avail- KEYWORDS multiple sclerosis, neuroprotection, sodium channel blockers able from animal models on the effects of four REVIEW CRITERIA sodium channel blockers, all of which are in PubMed was searched for articles published up to October 2007, including routine clinical use for other indications, and electronic early release publications.
    [Show full text]
  • Collaboration with Dr Stephen Waxman of Yale University to Evaluate Pharmacology of Nav1.7 Mutations in Chronic Pain Disorders Published: Oct 6, 2014 2:00 A.M
    Collaboration with Dr Stephen Waxman of Yale University to Evaluate Pharmacology of Nav1.7 Mutations in Chronic Pain Disorders Published: Oct 6, 2014 2:00 a.m. ET 16 24 CAMBRIDGE, England, October 6, 2014 /PRNewswire via COMTEX/ -- CAMBRIDGE, England, October 6, 2014 /PRNewswire/ -- Agreement follows a very successful preceding collaboration with Dr Waxman with findings due to be presented at IASP 2014 Convergence Pharmaceuticals Holdings Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain via a pharmacologically and genetically defined approach, today announces a collaboration with Dr Stephen Waxman, the Bridget Flaherty Professor of Neurology, Neurobiology, and Pharmacology at Yale University. The collaboration aims to identify patient groups likely to respond to Nav1.7 blockers and ultimately initiate clinical studies. Today's broader and more closely linked strategic collaboration follows an earlier one between Convergence and Dr Waxman, findings from which will be presented at The International Association for the Study of Pain via a poster in Buenos Aires, Argentina, October 6-11, 2014. A pharmacological evaluation of Nav1.7 gain of function mutations identified in patients suffering from chronic paroxysmal pain disorders such as erythromelalgia, small fibre neuropathy and paroxysmal extreme pain disorders[1], will be performed to discover selective drug therapy matched to a pain genotype. The ground breaking research conducted by Dr Waxman's laboratory has pioneered the field by showing that many Nav1.7 gain of function mutations lead to cellular hyper excitability which is an underlying cause of pain in patients with paroxysmal pain disorders[1].
    [Show full text]
  • ISNR Newsletter 2008
    Regeneration Research NEWSLETTER The Twelfth International Symposium on Neural Regeneration The Twelfth International Symposium on Discoveries/University of British Columbia). Neural Regeneration (ISNR) was held at the Guest attendees representing co-sponsoring Asilomar Conference Center in Pacific Grove, institutions at the planning meeting were Drs. California from December 5-9, 2007. The meet- Vivian Beyda (United Spinal Association) and ing was co-sponsored by the U.S. Department of Naomi Kleitman (NIH-NINDS). Veterans Affairs (Biological Laboratory Research The keynote speaker for this year’s sym- and Development and Rehabilitation Research posium was Stephen Waxman from Yale Medical and Development Service), the Paralyzed School. Featured talks were given by Melitta Veterans of America (Spinal Cord Research Schachner from Universitat Hamburg and Foundation), the National Institutes of Health Rutgers University, Douglas Kerr from Johns (National Institute of Neurological Disorders and Hopkins University School of Medicine, Steven Stroke, and Office of Rare Diseases), the Cramer from the University of California - Irvine, Christopher and Dana Reeve Foundation and Douglas Wallace from the University of California the United Spinal Association. Additionally, a - Irvine and Michael Fehlings from the University generous donation was received from the of Toronto. Shapiro Spinal Cord Research Foundation. The Symposium was organized by Dr. Roger Madison (Symposium Director, VA ISNR Staff Medical Center and Duke University, Durham, Director: Roger Madison, Ph.D. NC), and the program planning committee which included Drs. David Gardiner (University of Layout and Design: Frances Stuart California, Irvine), Jane Lebkowski (Geron Photo Credits: Rao Chadaram Corporation), Michael Sofroniew (University of California, Los Angeles) and John Steeves (International Collaboration on Repair Continued, page 3 OFFICE OF THE INTERNATIONAL SYMPOSIUM ON NEURAL REGENERATION June 2008 The Director’s Chair From the Office of the International Symposium on Neural Regeneration Roger D.
    [Show full text]
  • Transcript of PRF Podcast with Stephen Waxman
    Transcript of Podcast with Stephen Waxman Danielle Perro (DP): Hi, everyone, my name is Danielle Perro, and I was chosen as one of the PRF correspondents for this year’s NeuPSIG program. As a part of this program, I have the great pleasure of introducing leaders and interviewing leaders in the field of pain research. Now, I know that NeuPSIG has ended, but today I have the great pleasure of interviewing Dr. Stephen Waxman from the Yale School of Medicine. His research focuses on the application of molecular techniques to study neurological diseases, especially spinal cord injury, multiple sclerosis, and neuropathic pain. Thank you, Stephen, so much for being a part of this interview today. So my first question for Stephen here is, could you tell us a bit about the work that you’re doing and what principles from the work that you do can be generalized to other pain conditions and how we study them? Stephen Waxman (SW): Well, I am interested in pain in a reductionist sense. I would like to understand the molecules involved in generation of pain, particularly chronic pain, and so, my laboratory largely focuses on sodium channels. And some years ago, having done more on sodium channels and pain in in vitro models and animal models, cells in a dish, having done more on those topics than any sane person would want to hear about, we launched a worldwide search for families with inherited neuropathic pain. As neurologists, we see neuropathic pain all the time, but we never see families; they’re incredibly rare.
    [Show full text]
  • Voltage-Gated Sodium Channels and the Molecular Pathogenesis of Pain: a Review
    NZ, Department of Veterans Affairs Journal of Rehabilitation Research and Development Vol . 37 No . 5, September/October 2000 Pages 517—528 Voltage-gated sodium channels and the molecular pathogenesis of pain: A review Stephen G. Waxman, MD, PhD ; Theodore R. Cummins, PhD ; Sulayman D. Dib-Hajj, PhD; Joel A. Black, PhD Center of Excellence for Functional Restoration in MS and SCI, VA Medical Center, West Haven, CT 06516; Department of Neurology and PVA/EPVA Neuroscience Research Center, Yale University School of Medicine, New Haven, CT 06510 AbstractPain pathways begin with spinal sensory (dorsal root by changes in physiological properties that contribute to hyperex- ganglion, DRG) neurons that produce nociceptive signals and citability in these cells. Sodium channel expression is also altered convey them centrally. Following injury to the nervous system, in experimental models of inflammatory pain . The multiplicity of DRG neurons can become hyperexcitable, generating sponta- sodium channels, and the dynamic nature of their expression, neous action potentials or abnormal high-frequency activity that makes them important targets for pharmacologic manipulation in contributes to chronic pain . Because the generation of action the search for new therapies for pain. potentials in DRG neurons depends on voltage-gated sodium channels, an understanding of the expression and function of Key words: DRG neuron, hyperexcitability ; ion channels; these channels in DRG neurons is important for an understanding nerve injury; neuropathic pain. of pain. Molecular studies have indicated that at least eight dis- tinct voltage-gated sodium channels, sharing a common overall motif but encoded by different genes that endow them with dif- INTRODUCTION ferent amino acid sequences, are present within the nervous sys- tem.
    [Show full text]
  • An Incomplete Mosaic
    Researchers such as Anne-Julie Chabot-Doré, pictured in Luda Diatchenko’s lab at McGill University in Montreal, Canada, are searching for chronic pain genes. GENETICS An incomplete mosaic Although genetics studies have so far failed to revolutionize pain treatments, some researchers think that a host of discoveries are just around the corner. BY ERYN BROWN senses or promoting addiction. were not prohibitively expensive. “The studies But this is a search that has already gone on have not been done yet,” Diatchenko says. “It eurologist Stephen Waxman wants for a couple of decades. And although scientists will be an explosion — soon.” to understand how genes influence have discovered that genetics have a significant Pain-genetics researchers have pursued two chronic pain. He hopes that unravel- role in pain — anywhere from around 20% to main avenues of inquiry, says neuroscientist DIATCHENKO LUDA Nling the mystery will offer relief to the patients 60% of the variability in how people experience Stephen McMahon at King’s College London. he studies. Some are in agony because of old pain is attributable to differences in genes — The first strategy, taken by researchers such as injuries, others because of diabetic nerve no one has yet pinpointed any crucial smoking Waxman, is to study rare pain disorders that damage. And there are those who battle rare guns in DNA. And the complexity of the prob- run in families to identify single-gene muta- disorders such as inherited erythromelalgia, lem can be a bit depressing. “Once you real- tions. This approach has produced a handful experiencing searing pain in their extremities ize something is mediated by, say, 1,000 genes, of tantalizing leads.
    [Show full text]
  • The Search for a Pain Gene” with Stephen Waxman
    “Alabama to Beijing… and Back: The Search for a Pain Gene” with Stephen Waxman Transcript of Cerebrum Podcast Guest: Stephen Waxman, M.D., Ph.D. is the Flaherty Professor of Neurology, Neurobiology, and Pharmacology at Yale University, where he was chairman of neurology from 1986 to 2009. He founded Yale’s Neuroscience & Regeneration Research Center in 1988 and is its director. He previously worKed at Harvard, MIT, and Stanford, and is visiting professor at University College London. Waxman’s research defined the ion channel architecture of axons and its importance for axonal conduction. He demonstrated sodium channel plasticity in demyelinated axons which supports remission in multiple sclerosis. His molecule-to-man studies combining molecular genetics, molecular biology, and biophysics have illuminated the contribution of ion channels to human pain. A new class of medications for pain, based partly on his worK, has entered clinical trials. A member of the National Academy of Medicine, Waxman’s honors include the Dystel Prize and Wartenberg Award, Middleton Award and Magnuson Award, and the Soriano Award. He was honored in Great Britain with The Physiological Society’s Annual Prize, an accolade he shares with his heroes Andrew Huxley, John Eccles, and Alan Hodgkin. Host: Bill Glovin serves as editor of Cerebrum and the Cerebrum Anthology: Emerging Issues in Brain Science. He is also executive editor of the Dana Press and Brain in the News. Prior to joining the Dana Foundation, Mr. Glovin was senior editor of Rutgers Magazine and editor of Rutgers Focus. He has served as managing editor of New Jersey Success, editor of New Jersey Business magazine, and as a staff writer at The Record newspaper in Hackensack, NJ.
    [Show full text]
  • Keynote Speaker: Stephen G. Waxman, MD, Phd Stephen
    Keynote Speaker: Stephen G. Waxman, MD, PhD Stephen Waxman exemplifies the bridge between basic research and clinical medicine. He is the Bridget Flaherty Professor of Neurology, Neurobiology, and Pharmacology at Yale University and at VA Connecticut. He served as Chairman of Neurology at Yale from 1986 until 2009. He founded and is Director of the Neuroscience & Regeneration Research Center at Yale. He also holds an appointment as Visiting Professor at University College London. Prior to moving to Yale, Dr. Waxman worked at Harvard, MIT, and Stanford. Dr. Waxman received his BA from Harvard, and his MD and PhD degrees from Albert Einstein College of Medicine. His research, which uses tools from the “molecular revolution” to find new therapies that will promote recovery of function after injury to the brain, spinal cord, and peripheral nerves, has received international recognition. Dr. Waxman’s research has defined the ion channel architecture of nerve fibers, and demonstrated its importance for axonal conduction (Science, 1985). He demonstrated increased expression of sodium channels in demyelinated axons (Science, 1982), identified the channel isoforms responsible for this remarkable neuronal plasticity which supports remission in multiple sclerosis (PNAS, 2004), and delineated the roles of sodium channels in axonal degeneration (PNAS, 1993). He has made pivotal discoveries that explain pain after nerve injury. Most recently, in translational leaps from laboratory to humans, he carried out molecule-to-man studies combining molecular genetics, molecular biology, and biophysics to demonstrate the contribution of ion channels to human pain (Trends in Molec.Med, 2005; PNAS, 2006), led an international coalition that identified sodium channel mutations as causes of peripheral neuropathy (PNAS, 2012) and has used atomic-level modeling to advance pharmacogenomics (Nature Comm., 2012).
    [Show full text]
  • West Haven RRD Center Website Content
    VA Rehabilitation Research and Development Center of Excellence for Restoration of Nervous System Function West Haven, CT Stephen G. Waxman, MD, PhD, Director Jeffery D. Kocsis, PhD, Associate Director About the Center The goal of West Haven VA Rehabilitation Research and Development Center of Excellence is to advance rehabilitation through novel molecular and cellular approaches that will provide neuroprotection and neural repair, to preserve and restore function in people with nervous system disorders. Our initial focus on multiple sclerosis (MS) and spinal cord injury (SCI) has now expanded to include neuropathic pain, stroke and traumatic brain injury (TBI). These disorders affect the lives of many thousands of veterans. Our recent progress and plans include: • Demonstration that human bone marrow-derived stem cells improve functional outcome in stroke models. These preclinical studies are aimed at providing the basis for human clinical studies in stroke, and then, if appropriate, TBI. • Demonstration that bone marrow-derived stem cells, delivered intravenously, support remyelination within injured spinal cord in experimental models. This study brings us closer to novel stem cell-based therapies for people with MS and SCI. • Demonstration of sodium channel plasticity in MS. We have translated our observations from experimental models to human MS, and have demonstrated enhanced expression of sodium channels and established their molecular identities in demyelinated spinal cord axons from MS patients. We have delineated the channel that drives Ca2+-importing Na/Ca2+ exchange in degenerating axons in MS, thus identifying it as a therapeutic target. • Human genetic model of neuropathic pain. We have demonstrated a critical role for a specific ion channel in human pain.
    [Show full text]
  • Curriculum Vitae [PDF]
    Rhode Island Hospital & Brown University Curriculum Vitae CARL Y. SAAB, M.S., Ph.D. 593 Eddy Street, NAB 210 Last updated 9/18/2013 Providence, RI 02903 Telephone: +1(401) 444-4290 FAX: +1(401) 444-8052 E-mail: [email protected], [email protected] http://research.brown.edu/myresearch/Carl_Saab EDUCATION American University of Beirut B.S. Environmental Health 1994 M.S. Neuroscience 1997 University of Texas Medical Branch Ph.D. Neuroscience 2001 POSTGRADUATE TRAINING Yale University, New Haven, CT Postdoctoral Fellow, Department of Neurology 2001-2004 (Dr. Stephen Waxman) HONORS AND AWARDS Who's Who among Students in American Universities & Colleges 1998 University of Texas Medical Branch Certificate of Achievement in Teaching Physiology, Allied Health School Spring 1998 University of Wisconsin Travel award Symposium on Health and Emotion, Madison, Wisconsin 1998 & 1999 International Association for the Study of Pain Travel award 9th World Congress on Pain, Vienna, Austria Aug 1999 International Society for Magnetic Resonance in Medicine Travel award 7th meeting, Philadelphia, Pennsylvania May 1999 American Pain Society Young Investigator Travel Support & Citation Poster award 19th Annual Scientific Meeting, Atlanta, Georgia Nov 2000 Young Investigator Travel Support 20th Annual Scientific Meeting, Phoenix, Arizona Apr 2001 Baltic Summer School, Kiel, Germany Travel award Aug 2003 Rhode Island Hospital Research Celebration, New Investigator Award Finalist 10/22/2009 Who's Who in Medicine Higher Education 5/22/2010 Lifespan Corporation Executive Mentorship Program (Mentor Mr. Dan Wall, CEO of Bradley Hospital) Mar-Dec 2010 Selected from 12,000 employees the Lifespan Health System to participate in its mentoring program. Individuals are nominated by their supervisors who believe the individuals have the potential to grow within the system and be the leaders of the future for the organization.
    [Show full text]